PsyBio Therapeutics (FRA:PSYB) Debt-to-Equity : -0.06 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is PsyBio Therapeutics Debt-to-Equity?

PsyBio Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.09 Mil. PsyBio Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil. PsyBio Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €-1.56 Mil. PsyBio Therapeutics's debt to equity for the quarter that ended in Jun. 2023 was -0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for PsyBio Therapeutics's Debt-to-Equity or its related term are showing as below:

FRA:PSYB' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.21 Med: -0.06 Max: 7.03
Current: -0.06

During the past 2 years, the highest Debt-to-Equity Ratio of PsyBio Therapeutics was 7.03. The lowest was -0.21. And the median was -0.06.

FRA:PSYB's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs FRA:PSYB: -0.06

PsyBio Therapeutics Debt-to-Equity Historical Data

The historical data trend for PsyBio Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PsyBio Therapeutics Debt-to-Equity Chart

PsyBio Therapeutics Annual Data

Trend

Dec21

Dec22

Debt-to-Equity

-0.09

PsyBio Therapeutics Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Equity	Get a 7-Day Free Trial							7.04	-0.21	-0.09	-0.06	-0.06

Competitive Comparison of PsyBio Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, PsyBio Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PsyBio Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PsyBio Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where PsyBio Therapeutics's Debt-to-Equity falls into.

PsyBio Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

PsyBio Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.127	+	0)	/	-1.502
	=	-0.08

PsyBio Therapeutics's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.089	+	0)	/	-1.558
	=	-0.06

PsyBio Therapeutics (FRA:PSYB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

PsyBio Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of PsyBio Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

PsyBio Therapeutics (FRA:PSYB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PsyBio Therapeutics Corp (FRA:PSYB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PSYBF:USA PSYB:Canada

Address

4400 Sample Road, Suite 138, Coconut Creek, FL, USA, 33073

Website

https://www.psybiolife.com

PsyBio Therapeutics Corp is a biotechnology company. The company is engaged in the development of drugs intended for the treatment of mental illness and neurological disorders.

PsyBio Therapeutics (FRA:PSYB) Headlines

No Headlines